MYL3 Gene Mutation Analysis
The MYL3 gene is located in the short (p) arm of chromosome 3 at position 21 and encodes for myosin essential light chain 3 (ELC3) also known as the ventricular/cardiac isoform and ventricular/cardiac ELC. ELC3 is a 21.9 kDa protein composed of 195 amino acids and is the myosin light chain isoform present in cardiac muscle where it functions to modulate cardiac muscle contraction. Although ELC3 is a member of the EF-hand superfamily of proteins, it does not bind calcium at physiological levels. Due to the presence of positively charged lysine residues the N-terminal region is functionally unique and is able to bind actin and contribute to force production.
Mutations in MYL3 have been identified as a cause of familial hypertrophic cardiomyopathy that is associated with mid-left ventricular chamber hypertrophy. Inherited HCM is typically transmitted as an autosomal dominant heart disorder characterized by unexplained left ventricular (LV) hypertrophy (thickening) associated with non-dilated ventricular chambers. Pathological features include myocardial fiber hypertrophy, disorganized myocardial cells, interstitial fibrosis and thickened intra-myocardial coronary vessels. The majority of HCM patients are asymptomatic. Only about 25% develop symptom such as dyspnea, syncope, collapse, palpitations, and chest pain. The disorder has inter- and intra-familial variability ranging from benign cases to malignant forms with a high risk of cardiac failure and sudden cardiac death.
HCM is the most common cause of sudden cardiac death in young people and has a prevalence of 1:500 in the general adult population. The majority of the mutations in HCM are missense, insertion/deletion and frame-shift mutations. To date, nine HCM causing mutations to have been described in MYL3. Mutations in MYL3 account for < 3% of cases of inherited HCM.
- As an aid in diagnosis of familial hypertrophic cardiomyopathy and dilated cardiomyopathy
- Carrier screening for relatives and those with the family history
- Prenatal carrier screening for those with the family history
Negative for mutations analyzed (No pathogenic variant or mutation detected)
Whole blood (EDTA).
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: Unacceptable
- J Muscle Res Cell Motil. 2015; 36: 433-445. [PMID: 26385864]
- Biochem Res Int. 2012;2012: 685108. [PMID: 22957257]
- Am J Physiol Heart Circ Physiol. 2007 Apr;292(4):H1643-54. [PMID: 17142342]
- Circ J. 2019;83: 1908-1916. [PMID: 31308319]
- Heart Fail Rev. 2019;24: 439-459. [PMID: 30852773]
- Cardiovasc Diagn Ther. 2019; 9: S388-S415. [PMID: 20869644]
- Yale J Biol Med. 2017; 90: 433-448. [PMID: 28955182]
- J Hum Genet. 2016;61: 41-50. [PMID: 26178429]
- Post-Genomic Cardiology, In: Chapter 13 Cardiomyopathies. 2007. 363–413. doi:10.1016/b978-012373698-7/50013-9.